SOPHiA GENETICS (NASDAQ: SOPH) CMO offloads 5,000 shares

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on 2026-08-25. The shares were sold at a weighted average price of $8.6793 per share, in multiple trades between $8.37 and $8.84, pursuant to a Rule 10b5-1(c) trading plan. Following this transaction, Menu owned 213,387 Ordinary Shares directly.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,000 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	5,000	$8.6793	$43K

Holdings After Transaction: Ordinary Shares — 213,387 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.37 to $8.84, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 Ordinary Shares Weighted average sale price: $8.6793 per share Sale price range: $8.37 to $8.84 per share +1 more

4 metrics

Shares sold 5,000 Ordinary Shares Non-derivative sale on 2026-08-25

Weighted average sale price $8.6793 per share Ordinary Shares sold on 2026-08-25

Sale price range $8.37 to $8.84 per share Multiple transactions included in the reported sale

Shares owned after transaction 213,387 Ordinary Shares Direct holdings of Philippe Menu following the sale

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider transaction did SOPH disclose for Philippe Menu?

SOPHiA GENETICS SA disclosed that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on 2026-08-25 under a pre-arranged Rule 10b5-1(c) trading plan, at a weighted average price of $8.6793 per share.

At what prices were Philippe Menu’s SOPH shares sold?

The filing states a weighted average price of $8.6793 per share. Footnotes explain the 5,000 shares were sold in multiple transactions at prices ranging from $8.37 to $8.84, inclusive.

How many SOPH shares does Philippe Menu hold after this sale?

After the sale, Chief Medical Officer Philippe Menu directly owned 213,387 Ordinary Shares of SOPHiA GENETICS SA, according to the reported post-transaction holdings figure.

Was the SOPH insider sale made under a Rule 10b5-1 plan?

Yes. The filing’s checkbox and a footnote state that the transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, indicating the trades were pre-arranged under that rule.

How many SOPH shares in total were sold in this Form 4?

The Form 4 reports a single transaction in which 5,000 Ordinary Shares of SOPHiA GENETICS SA were sold by Chief Medical Officer Philippe Menu on 2026-08-25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/26/2026 - 04:06 PM Accepted by SEC EDGAR 08/26/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/25/2026		S		5,000(1)	D	$8.6793(2)	213,387	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.37 to $8.84, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)